Prostatype Genomics AB today publishes its interim report for the first half of 2024. The full interim report is attached and can also be downloaded from the company's website, www.prostatypegenomics.com.
Summary of the first half of 2024
1 January - 30 June 2024
• Net sales amounted to 115 TSEK (447)
• EBITDA (earnings before interest, taxes, depreciation, and amortization) amounted to -18,437 TSEK (-19,575)
• Cash flow from current operations amounted to -23,211 TSEK (-19,200)
• Total cash flow for the period amounted to -935 TSEK (476)
• Earnings per share amounted to -0.02 SEK (-0.17)
CEO Fredrik Rickman comments:
"During the first half of 2024, a new promising chapter in the history of Prostatype Genomics began when we entered the US market with our genetic test Prostatype®, a market with annual sales of approximately 2 billion SEK and a potential that we estimate to be at least 6 billion SEK. At the same time, a multicentre study was completed in Spain with positive results, which means that many private healthcare providers and university hospitals in the country now want to start using Prostatype® as part of their clinical practice. We now have an exciting second half of the year ahead of us, with expected inclusion in Medicare's reimbursement system (currently approx. 3,700 USD per test) in the United States in Q4 as the most important milestone."
Contacts
For further information about Prostatype Genomics, please contact:
Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01.
e-mail: fredrik.persson@prostatypegenomics.com
Certified Advisor
Carnegie Investment Bank AB (publ), +46 (0)73 856 42 65, certifiedadviser@carnegie.se
About Us
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.
This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-26 08:00 CEST.
